Skip to main content
IMS Events Main banner

  1. Home

  • Wednesday, Sep 17th
    11:40 - 11:50 East Coast USA Time
    (OA-35) TRIgnite- 1Study, Phase 1, First-in-Human Study of ISB 2001: A BCMAxCD38xCD3-Targeting Trispecific Antibody for Patients with Relapsed/Refractory Multiple Myeloma (RRMM)—Dose Escalation (DE) Results
    Location: Room 701
    Abstract Presenter: Hang Quach, MBBS(Hons) FRACP FRCPA MD (she/her/hers) – St Vincent’s Hospital Melbourne, University of Melbourne, VIC, Australia
    Myeloma Novel Drug Targets and agents
  • Wednesday, Sep 17th
    12:02 - 12:08 East Coast USA Time
    (PA-324) AKR1B1/NAT10 Mediate IL4I1 ac4C Modification to Regulate Tryptophan Metabolism and Promote Multiple Myeloma Proliferation
    Location: Room 714A
    Abstract Presenter: Rongfang Wei, PhD – Department of Hematology, The Eighth Affiliated Hospital, Sun Yat-sen University
    Myeloma Novel Drug Targets and agents
  • Wednesday, Sep 17th
    12:20 - 12:26 East Coast USA Time
    (PA-307) Iberdomide (Iber) Treatment (Tx) Enhances Manufactured Chimeric Antigen Receptor (Car) T Cell Expansion And Functionality And Is Immunostimulatory In Patients Post-Car T Cell Therapy
    Location: Room 714A
    Abstract Presenter: Michael D. Amatangelo, PhD – Bristol Myers Squibb, Summit, NJ, USA
    Myeloma Novel Drug Targets and agents
  • Thursday, Sep 18th
    12:44 - 12:50 East Coast USA Time
    (PA-295) Tumor-reactive γδ T Cells Mediate Responses to the Antibody Drug Conjugate Belantamab Mafodotin in Multiple Myeloma
    Location: Room 714A
    Abstract Presenter: Liam D. Hendrikse, PhD – University Health Network
    Myeloma Novel Drug Targets and agents
  • Thursday, Sep 18th
    15:16 - 15:24 East Coast USA Time
    (OA-66) Maintenance Therapy with Belantamab, Pomalidomide and Dexamethasone in High-risk Myeloma Patients: A Phase 2 Study with a Safety Run-in - Interim Analysis
    Location: Hall FG
    Abstract Presenter: Ajay K. Nooka, MD, MPH, FACP (he/him/his) – Winship Cancer Institute of Emory University
    Myeloma Novel Drug Targets and agents
  • Friday, Sep 19th
    12:29 - 12:35 East Coast USA Time
    (PA-321) Belantamab Mafodotin plus Lenalidomide/Dexamethasone in Newly Diagnosed Patients with Multiple Myeloma: Long-Term Efficacy and Safety Results from the Phase 1/2 BelaRd Study
    Location: Room 714A
    Abstract Presenter: Evangelos Terpos, MD (he/him/his) – Department of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece
    Myeloma Novel Drug Targets and agents
  • Saturday, Sep 20th
    11:00 - 11:10 East Coast USA Time
    (OA-37) Novel NKp30-directed Bispecific Natural Killer Cell Engagers Targeting GPRC5D or CD38 for the Treatment of Multiple Myeloma
    Location: Room 718
    Abstract Presenter: Dorothee Winterberg, PhD (she/her/hers) – University Medical Center Schleswig-Holstein
    Myeloma Novel Drug Targets and agents
  • Saturday, Sep 20th
    11:10 - 11:20 East Coast USA Time
    (OA-40) A Novel Dual Proteasome and HDAC6 Inhibitor I3MV-8b Potentiates Anti-CD38 Monoclonal Antibody Efficacy in Multiple Myeloma
    Location: Room 718
    Abstract Presenter: Lanting Liu, MD – State Key Laboratory of Experimental Hematology; National Clinical Research Center for Blood Diseases;Haihe Laboratory of Cell Ecosystem; Institute of Hematology & Blood Diseases Hospital; Chinese Academy of Medical Sciences & Peking Union Medical College
    Myeloma Novel Drug Targets and agents
  • Saturday, Sep 20th
    11:20 - 11:30 East Coast USA Time
    (OA-38) A Phase I/II Single Arm Study of Belantamab Mafodotin, Carfilzomib and Dexamethasone in Patients with Relapsed Multiple Myeloma (Mm): Primary Analysis. Amarc 19-02 Belacard Study
    Location: Room 701
    Abstract Presenter: Masa Lasica, MBBS, FRACP, FRCPA – St Vincent's Hospital Melbourne
    Myeloma Novel Drug Targets and agents
  • Saturday, Sep 20th
    11:20 - 11:30 East Coast USA Time
    (OA-39) Targeting PHF19 Inhibits Myeloma progression and Increases IMiDs Sensitivity by Epigenetically Regulating MYC and IRF4 Pathway
    Location: Room 718
    Abstract Presenter: Xiyue Sun, PhD student (she/her/hers) – State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China.
    Myeloma Novel Drug Targets and agents
  • Saturday, Sep 20th
    11:30 - 11:40 East Coast USA Time
    (OA-34) Exploring Molecular Glues to Activate Proteasomes and Develop Shared and Personalized Neoantigen-Based Therapeutics in Multiple Myeloma
    Location: Room 718
    Abstract Presenter: James J. Driscoll, MD, PhD (he/him/his) – Case Western Reserve University
    Myeloma Novel Drug Targets and agents